Hepatic Impairment · Chapter 7
Benzodiazepines & Sedative-Hypnotics: the LOT Rule
The highest-stakes sedative decision in liver disease — because benzodiazepines are the classic pharmacologic trigger of hepatic encephalopathy, and one mnemonic sorts the safe ones from the dangerous ones.
Bottom Line Up Front
The 30-second version
- This is the highest-stakes sedative decision in liver disease, because benzodiazepines are the classic pharmacologic trigger of hepatic encephalopathy.
- The LOT rule: Lorazepam, Oxazepam, Temazepam are cleared by glucuronidation (Phase II), which liver disease largely spares, and they have no active metabolites — so they're the preferred benzodiazepines. The oxidized, long-acting ones (diazepam, chlordiazepoxide) accumulate and precipitate encephalopathy: avoid them.
- The biggest real-world application is alcohol withdrawal in the patient with alcohol-associated liver disease: reach for lorazepam or oxazepam, not chlordiazepoxide or diazepam.
- Z-drugs aren't a loophole: zolpidem (reduce — 5 mg IR / 6.25 mg ER; avoid in severe, where it can contribute to encephalopathy), zaleplon (5 mg; not in severe), eszopiclone (≤2 mg in severe), ramelteon (not in severe). And avoid anticholinergic antihistamine “sleep aids” (diphenhydramine, hydroxyzine).
- Whatever you choose: lowest dose, shortest duration, and treat new sedation or confusion as encephalopathy until proven otherwise.
How to Approach It
The governing fact comes straight from the framework chapter: Phase II glucuronidation is relatively preserved when Phase I oxidation falters. That single distinction sorts the benzodiazepines almost completely. Three moves follow:
- Default to the LOT benzodiazepines (glucuronidated) whenever a benzodiazepine is genuinely needed.
- Treat every sedative as a potential encephalopathy trigger — lowest dose, shortest course, and counsel the patient and family about confusion.
- Don't reach for a “safer-sounding” alternative without checking it — the Z-drugs and the antihistamines carry their own hepatic and encephalopathy liabilities.
The LOT Rule
The single most useful mnemonic in hepatic psychopharmacology:
LOT
Lorazepam · Oxazepam · Temazepam — the benzodiazepines that are safe(r) in liver disease.
Why these three: they bypass Phase I CYP oxidation and are cleared by Phase II glucuronidation directly into inactive, water-soluble metabolites that the kidney excretes. As Chapter 1 laid out, glucuronidation is the metabolic route relatively preserved in liver disease, while oxidation falters earlier and harder. So the LOT agents are cleared at close to their normal rate even in cirrhosis, generate no active metabolites, and therefore don't pile up into prolonged sedation.
Contrast the oxidized benzodiazepines. Diazepam and chlordiazepoxide are the archetypes: both are oxidized to long-lived active metabolites (diazepam → desmethyldiazepam, with a half-life measured in days) before they're ever conjugated. In a cirrhotic, that oxidation step is impaired, the parent drug and its active metabolites accumulate, and the result is deep, prolonged sedation that can tip into overt encephalopathy. The same caution applies to clonazepam, alprazolam, clorazepate, flurazepam, and midazolam — all oxidatively metabolized.
The rule in one line: in liver disease, if you need a benzodiazepine, use an LOT agent.
One caveat worth carrying: the evidence is strongest for lorazepam (its clearance is essentially unchanged in cirrhotic patients on the FDA label) and oxazepam; temazepam shares the glucuronidation pathway but has thinner cirrhosis-specific data. And glucuronidation is only relatively preserved — for some substrates (lamotrigine among them, as the mood-stabilizer chapter notes) it still erodes in advanced cirrhosis. “Preserved” means the LOT agents hold up far better than the oxidized ones, not that liver disease is irrelevant to them.
Dosing by Agent
Use the lowest effective dose for the shortest duration throughout, regardless of tier.
| Agent | In hepatic impairment | Key note |
|---|---|---|
| Lorazepam / Oxazepam / Temazepam | Preferred benzodiazepines; reduce dose, still go low and slow | Glucuronidated (Phase II preserved); no active metabolites. The LOT agents. |
| Diazepam | Avoid | Oxidized to desmethyldiazepam (half-life in days); accumulates → prolonged sedation, encephalopathy. |
| Chlordiazepoxide | Avoid | Oxidized, long-acting active metabolites; the same accumulation trap (notably in alcohol withdrawal). |
| Clonazepam / alprazolam / midazolam | Use with caution; reduce | Oxidatively (CYP) metabolized → reduced clearance in cirrhosis. LOT agents are preferable. |
| Zolpidem | Mild–moderate (formulation-specific): 5 mg IR / 6.25 mg ER / 1.75 mg low-dose SL; avoid in severe | Label: may contribute to encephalopathy in severe impairment. |
| Zaleplon | 5 mg in mild–moderate; not recommended in severe | Clearance falls ~70% (compensated) to ~87% (decompensated cirrhosis). |
| Eszopiclone | No adjustment mild–moderate; severe: do not exceed 2 mg | Systemic exposure doubles in severe impairment. |
| Ramelteon | Exposure rises steeply (~4× mild, >10× moderate); use cautiously even in mild–moderate; not recommended in severe | Melatonin-receptor agonist, no abuse liability, but heavy first-pass metabolism. |
| Diphenhydramine / hydroxyzine | Avoid as sleep aids | Anticholinergic → constipation + clouded sensorium, both HE precipitants. |
Why Benzodiazepines Precipitate Encephalopathy
Of all the triggers of hepatic encephalopathy — GI bleeding, infection, constipation, electrolyte derangement — sedative drugs are the one most directly under the prescriber's control, and benzodiazepines are the prototype. The mechanism is intuitive: hepatic encephalopathy is, in part, a state of excess GABAergic, inhibitory tone in the brain, and benzodiazepines add to exactly that tone. Layer a benzodiazepine — especially an accumulating, oxidized one — onto a brain already drifting toward encephalopathy, and you can push it over the edge.
Two practical consequences follow:
- Prevention. Prefer LOT agents, lowest dose, shortest duration — and ask whether a benzodiazepine is needed at all.
- Recognition. In a cirrhotic on any sedative, new drowsiness or confusion is hepatic encephalopathy until proven otherwise. Don't write it off as “just the medication” — look for the full picture (asterixis, ammonia, precipitants) the way the framework chapter describes.
The Alcohol-Withdrawal Application
The highest-volume place this rule earns its keep is alcohol withdrawal — because the patients most likely to be withdrawing are precisely those most likely to have alcohol-associated liver disease. Benzodiazepines are first-line for alcohol withdrawal (they're cross-tolerant with alcohol), so the choice of agent is unavoidable, and the LOT rule makes it:
- Use lorazepam or oxazepam (glucuronidated, predictable in liver disease) rather than chlordiazepoxide or diazepam (oxidized, accumulating) when the patient has significant liver disease.
- Accept the trade-off. The classic teaching gives up the smoother, self-tapering kinetics of the long-acting agents (an advantage in a healthy liver) for the predictability of the LOT agents (essential in a sick one).
- Stay cautious in severe disease. Even LOT benzodiazepines must be used carefully and monitored — the risk of over-sedation and precipitating encephalopathy doesn't vanish, it just becomes manageable. Symptom-triggered (CIWA-guided) dosing keeps total exposure as low as possible — though note that CIWA leans on tremor, agitation, and confusion, which overlap with baseline hepatic encephalopathy, so interpret the score with care in a patient who already has HE.
Medications for alcohol-use-disorder maintenance (naltrexone, acamprosate) and the broader management of alcohol-associated liver disease are covered in the alcohol and cirrhosis chapter later in the course.
Z-Drugs & Other Hypnotics
The Z-drugs are not the hepatic loophole they're sometimes assumed to be — they're hepatically metabolized and can contribute to encephalopathy just as benzodiazepines do:
- Zolpidem: the hepatic dose is formulation-specific — 5 mg immediate-release, 6.25 mg extended-release, 1.75 mg low-dose sublingual — in mild–moderate impairment; avoid in severe, where the label specifically warns it may contribute to encephalopathy.
- Zaleplon: 5 mg in mild–moderate (clearance falls ~70% in compensated and ~87% in decompensated cirrhosis); not recommended in severe.
- Eszopiclone: no adjustment in mild–moderate; in severe, exposure doubles — do not exceed 2 mg.
- Ramelteon: a melatonin-receptor agonist with no abuse liability and a lower theoretical encephalopathy risk — but its heavy first-pass metabolism means exposure climbs steeply in liver disease (roughly 4-fold in mild, more than 10-fold in moderate impairment), so use it cautiously even in mild–moderate disease and not at all in severe. Orexin antagonists are likewise not recommended in severe (lemborexant is capped at 5 mg in moderate impairment; suvorexant needs no moderate adjustment).
- Avoid as sleep aids: diphenhydramine and hydroxyzine — their anticholinergic load slows the gut (constipation is itself an HE precipitant) and clouds the sensorium. Buspirone, a non-benzodiazepine anxiolytic, is also hepatically metabolized and accumulates — reduce, and avoid in severe disease.
The Action Ladder
Child-Pugh A (5–6)
LOT benzodiazepines at usual-to-reduced doses; Z-drugs reduced (zolpidem 5 mg IR / 6.25 mg ER, zaleplon 5 mg). Avoid the oxidized long-acting benzodiazepines.
Child-Pugh B (7–9)
LOT agents, lowest effective dose, short course; zolpidem 5 mg IR / 6.25 mg ER, zaleplon 5 mg; eszopiclone and ramelteon with caution. Avoid diazepam/chlordiazepoxide and anticholinergic antihistamines. CIWA-guided dosing for withdrawal.
Child-Pugh C (10–15)
Even LOT benzodiazepines cautiously and monitored (the encephalopathy risk persists). Avoid zolpidem (label) and ramelteon (not recommended); minimize all sedatives; treat any new confusion as HE.
Clinical Pearls
Pearls
- LOT = Lorazepam, Oxazepam, Temazepam — glucuronidated, no active metabolites, the benzodiazepines for liver disease.
- Avoid the oxidized, long-acting benzodiazepines (diazepam, chlordiazepoxide) — active metabolites accumulate and precipitate encephalopathy.
- Alcohol withdrawal in liver disease → lorazepam/oxazepam, CIWA-guided, lowest exposure.
- Benzodiazepines are the classic HE precipitant — new confusion on a sedative is encephalopathy until proven otherwise.
- Z-drugs aren't a loophole: zolpidem 5 mg IR / 6.25 mg ER (avoid severe), zaleplon 5 mg (not severe), eszopiclone ≤2 mg severe, ramelteon not in severe (exposure climbs >10× in moderate).
- Avoid anticholinergic “sleep aids” (diphenhydramine, hydroxyzine) — they compound the encephalopathy risk.
- Don't lean on flumazenil — its benefit in benzo-related or hepatic encephalopathy is transient, not a substitute for avoiding the offending sedative.
Red Flags — Stop and Reassess
Hold or reconsider
- A cirrhotic started on diazepam or chlordiazepoxide (including for alcohol withdrawal) — switch to an LOT agent.
- New drowsiness, confusion, or asterixis after any sedative in a cirrhotic — work up hepatic encephalopathy; don't attribute it to the drug alone.
- Zolpidem in severe hepatic impairment, or ramelteon/orexin antagonists in severe — over the labeled limit.
- An anticholinergic antihistamine used as a sleep aid in cirrhosis — constipation plus sedation, both HE precipitants.
- Escalating benzodiazepine doses for “agitation” in a confused cirrhotic — the agitation may be encephalopathy, which benzodiazepines worsen.
Patient Counseling Script
Plain-language script
“This medicine can affect alertness, and in liver disease that matters more than usual — sedatives can sometimes bring on confusion. We've chosen one your liver handles more predictably, and we'll use the lowest dose for the shortest time. Tell us, or have someone with you tell us, if you become unusually sleepy, confused, unsteady, or hard to wake. Please don't combine it with alcohol or other sleep or calming medicines — including over-the-counter ones like diphenhydramine — without checking with us. And if you've been on it a while, don't stop it suddenly.”
EMR / Documentation Template
References
- U.S. FDA Prescribing Information — lorazepam, oxazepam, temazepam (Phase II glucuronidation, inactive metabolites) vs diazepam, chlordiazepoxide (oxidative metabolism, long-acting active metabolites). Accessed June 2026.
- Peppers MP. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996;16(1):49–57.
- U.S. FDA. Ambien / Ambien CR (zolpidem) Prescribing Information — mild–moderate hepatic impairment: 5 mg (IR) / 6.25 mg (ER) / 1.75 mg (low-dose sublingual); avoid in severe (may contribute to encephalopathy). Accessed June 2026.
- U.S. FDA. Sonata (zaleplon) Prescribing Information — 5 mg in mild–moderate; not recommended in severe (clearance ↓ ~70% compensated / ~87% decompensated cirrhosis). Accessed June 2026.
- U.S. FDA. Lunesta (eszopiclone) Prescribing Information — no adjustment mild–moderate; severe: do not exceed 2 mg (exposure doubled). Accessed June 2026.
- U.S. FDA. Rozerem (ramelteon) Prescribing Information; LiverTox (NCBI) — exposure increased ~4× (mild) and >10× (moderate); use cautiously in mild–moderate; not recommended in severe. Accessed June 2026.
- Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: AASLD/EASL practice guideline. Hepatology. 2014;60(2):715–735 — sedatives/benzodiazepines as HE precipitants.
- Review: Management of psychiatric disorders in patients with hepatic and gastrointestinal diseases (2022) — LOT agents preferred for alcohol-withdrawal detoxification in liver disease.
Last reviewed June 2026. Part of the Psychiatry Education Forum Academy; for clinician education — it supports, and does not replace, individual clinical judgment and current local protocols.
This is a free preview of the course.
You've just seen the single highest-yield rule in the course. The full Psychotropics in Hepatic Impairment guide carries the same copy-paste decision tables, dosing caps, EMR templates, and red-flag lists across all twelve chapters — antidepressants, antipsychotics, mood stabilizers, stimulants, the hepatotoxic watchlist, and the quick-reference dosing table.
Educational use only. Refer to the sources cited above and current prescribing information for clinical decisions. Psychiatry Education Forum and authors assume no liability for use of this material.
Responses